Press releases
- Invitation to Immunovia's Q1 presentation
- Immunovia announces updated financial calendar
- Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test
- Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test - moving forward towards model-development study
- Immunovia Publishes Full Year Report for 2023
- Invitation to Immunovia's Q4 presentation
- Immunovia appoints Norma Alonzo Palma as new Vice President of Clinical and Medical Affairs
More ▼
Key statistics
On Wednesday, Immunovia AB (publ) (1YR:BER) closed at 0.1968, 4,700.00% above the 52 week low of 0.0041 set on Oct 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.1818 |
---|---|
High | 0.1968 |
Low | 0.177 |
Bid | 0.1552 |
Offer | 0.2385 |
Previous close | 0.1818 |
Average volume | 0.00 |
---|---|
Shares outstanding | 45.29m |
Free float | 34.12m |
P/E (TTM) | -- |
Market cap | 86.68m SEK |
EPS (TTM) | -8.27 SEK |
Data delayed at least 15 minutes, as of Apr 24 2024 20:43 BST.
More ▼